Bioavailability study with LCZ696

Phase 1

• Conditions: Study in healthy subjects; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2017-001803-57-Outside-EU/EEA
• Lead Sponsor: ovartis Pharmaceuticals Corp

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-08-14
• Last Update Posted: 21 August 2017

Recruitment & Eligibility

• Status: A
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Healthy male and female subjects of non-child bearing potential, age 18 to 55 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
Other protocol-defined inclusion criteria may apply.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Use of investigational drugs within 30 days or 5 half-lives of enrollment, whichever is longer. History of symptomatic orthostatic hypotension or syncope or clinically significant ECG abnormalities.
Other protocol-defined exclusion criteria may apply.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified